V
Vogenx
VOGXNewly listed · final prospectus verifiedVogenx, Inc. · Nasdaq · Clinical-stage biotechnology · latest filing 2026/08/12
One-minute decisionWATCHAnalysis confidence · Medium-high
Newly listed — review valuation, deal quality and post-IPO supply before acting
Vogenx, Inc. began trading on 2026-08-12 at an IPO price of $13.00; the final prospectus and offer terms are linked to SEC EDGAR.
🔒 Detailed transaction interpretation is available with Pro- Business and development direction
A clinical-stage developer of therapies for metabolic disorders including post-bariatric hypoglycemia.
Current business Clinical-stage biotechnology100%
Future development Future direction not yet disclosedNot quantified
PRIMARY SEC DOCUMENT
SEC source document
The filing's first page is kept visible in the overview so the issuer, document type and filing basis can be checked before reading the analysis.
- Document
- 424B4
- Filed
- 2026/08/12
- Source
- SEC EDGAR
DECISION DRIVERS
Three risks and three checkpoints
PUBLIC RISK PREVIEW
Valuation and future tradable supply require continued review
🔒 The evidence, figures, severity and remaining risk review are available with Pro.
BOOKRUNNERS / LEAD UNDERWRITERSSole book-running manager
CONFIRMED- 1JonesTrading Institutional Services LLC100.00%6,250,000 shares
IPO CAPITAL QUALITY
Where each offered share directs value
Issuer capital
Selling-holder liquidity
Operations / R&D
Debt / offer costs
CalculationSharesValueReference
Pre-offer basis
Basic post-offer
Fully diluted
PRO SCENARIO LAB
IPO valuation scenario simulator
Adjustable assumptions are visible after unlocking.
Economic ownershipWho receives the economic upside.Voting controlWho can approve major corporate actions.
CONTROLLING PARTY
424B4 · 2026/08/12
- Voting
- Economic
- As of
- 2026/08/12
POTENTIAL SUPPLY PRESSURE
Next public checkpoint：First post-IPO filing and lock-up schedule
- Initial float
- Potential float
- Multiple
- Increase
Initial floatTime triggerExpected unlock
Revenue
Net result
Cash
Cash runway
INVESTOR DUE DILIGENCE
Evidence completeness and operating runway
Final prospectus, offer price, listing date and headline financial evidence reconciled
Valuation and future tradable supply require continued review
- Potential impact
- Monitor
- First post-IPO filing and lock-up schedule
- Evidence
- 424B4 · 2026/08/12
- Potential impact
- Monitor
- Evidence
- 424B4 · 2026/08/12
- Potential impact
- Monitor
- Evidence
- 424B4 · 2026/08/12
PUBLIC CHANGE COUNT0material changes identified in the latest comparison
LATEST DOCUMENT424B42026/08/12
IPO177 PRO
Unlock each change, investor impact and evidence locator
Document424B4✓ Verified against the SEC source · SEC source document
Filed2026/08/121 public filings identified
Research updated2026/08/12SEC EDGAR
Evidence coverage84%Final prospectus, offer price, listing date and headline financial evidence reconciled
What remains missing16% of the evidence set remains unresolved. This may affect unconfirmed pricing, valuation, dilution or supply conclusions; no missing term is estimated.
View the filing's actual first page ＋